Editorial: Approval of new drugs for glioblastoma

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 617-618

  Weller, Michael ^a   Stupp, Roger ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CILENGITIDE; ENZASTAURIN; LOMUSTINE; NEW DRUG; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT;

DRUG APPROVAL; DRUG HALF LIFE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; REBOUND; SIDE EFFECT; STATISTICS; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; GLIOBLASTOMA; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74049116931     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283327cc1     Document Type: Editorial

References (0)